Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study

Wennberg, Patrik; Rolandsson, Olov; Jerden, Lars; Boeing, Heiner; Sluik, Diewertje; Kaaks, Rudolf; Teucher, Birgit; Spijkerman, Annemieke; de Mesquita, Bas Bueno; Dethlefsen, Claus; Nilsson, Peter; Noethlings, Ute

Published in:
BMJ Open

DOI:
10.1136/bmjopen-2011-000760

Published: 2012-01-01

Citation for published version (APA):
Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study

Patrik Wennberg,¹ Olov Rolandsson,¹ Lars Jerdén,² Heiner Boeing,³ Diewertje Sluij,³ Rudolf Kaaks,⁴ Birgit Teucher,⁴ Annemiek Spijkerman,⁵ Bas Bueno de Mesquita,⁵ Claus Dethlefsen,⁶ Peter Nilsson,⁷ Ute Nöthlings⁸

ABSTRACT

Objectives: To investigate whether low self-rated health (SRH) is associated with increased mortality in individuals with diabetes.


Participants: 3257 individuals (mean ± SD age was 55.8±7.6 years and 42% women) with confirmed diagnosis of diabetes mellitus.

Primary outcome measure: The authors used Cox proportional hazards modelling to estimate HRs for total mortality controlling for age, centre, sex, educational level, body mass index, physical inactivity, smoking, insulin treatment, hypertension, hyperlipidaemia and history of myocardial infarction, stroke or cancer.

Results: During follow-up (mean follow-up ± SD was 8.6±2.3 years), 344 deaths (241 men/103 women) occurred. In a multivariate model, individuals with low SRH were at higher risk of mortality (HR 1.38, 95% CI 1.10 to 1.73) than those with high SRH. The association was mainly driven by increased 5-year mortality in men and was stronger among individuals with body mass index <25 than among obese individuals.

Conclusions: Low SRH was associated with increased mortality in individuals with diabetes after controlling for potential confounders. The association was statistically significant in men only. There was no indication of heterogeneity across centres.

INTRODUCTION

Patients with diabetes have a 1.5–2.5-fold higher risk of death compared to a non-diabetic population.¹–⁴ The excess mortality in patients with diabetes is mainly caused by a higher risk of cardiovascular (CV) mortality,³ ⁴ but mortality due to cancer is also increased.⁵ It is of great importance to identify patients with diabetes with high risk of CV morbidity and mortality early on in the disease process in order to intervene with medication and lifestyle changes.⁶ Hence, risk engines⁷ or risk scores⁸ have been developed to identify the subjects at highest risk of developing CV. None of these tools have used subjective measures of health.

Self-rated health (SRH) is a subjective measure of health usually defined by

ARTICLE SUMMARY

Article focus

- Is low self-rated health (SRH) associated with increased mortality in individuals with diabetes?
- If so, is the association between SRH and mortality in individuals with diabetes moderated by socio-demographic and health-related variables?

Key messages

- Low SRH was associated with increased mortality in individuals with diabetes after controlling for established risk factors. The association was homogeneous across the four European Prospective Investigation into Cancer and Nutrition centres situated in three different European countries.

Strengths and limitations of this study

- To our knowledge, this is the first study that evaluates this research question in a population-based cohort of individuals with diabetes with long-term follow-up (up to a maximum of 14 years) in different European countries.

- The association between low SRH and mortality remained robust after controlling for potential confounders, including previous myocardial infarction, stroke or cancer, but we cannot rule out residual confounding from other comorbidity that was not assessed at baseline.
responses to a single question such as ‘How do you rate your health?’ SRH has been associated with future health outcomes, such as cardiovascular events and mortality both in representative community samples and in defined patient cohorts. Although there is no consensus on what SRH really represents, SRH is drawing increasingly attention as a key parameter in healthcare, including health policy evaluation, population surveys and research. Previous research in different populations has suggested that the predictive strength of SRH for subsequent mortality may differ by sex, age, race, education level and experience of chronic disease. Studies evaluating SRH among individuals with diabetes are scarce. One previous study showed that SRH predicted vascular events and major complications in patients with diabetes.

The primary aim of this study was to investigate whether low SRH is associated with increased mortality in individuals with diabetes. Prospective studies investigating this research question have been restricted to short-term mortality (up to 4 years), whereas we can present data from a study with a mean follow-up of 8.6 years. As a secondary aim we investigated whether socio-demographic and health-related variables moderate the association between SRH and mortality in this cohort of individuals with diabetes.

**METHODS**

**Study population**

The study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is an ongoing cohort study, which consists of 519,978 men and women from 10 European countries. A detailed description of the study design and methods can be found elsewhere. Participants were 35–70 years at enrolment between 1992 and 2000 and were recruited predominantly from the general population residing in a given geographic area. Participants gave their written consent, and the study was approved by the ethical review boards of the International Agency for Research on Cancer and by the review boards at the local centres where participants had been recruited for the EPIC study. Originally, the EPIC centres in Denmark, Germany, Italy, Spain, Sweden and the Netherlands contributed 7048 cases of self-reported diabetes at baseline. Self-reports of diabetes obtained at baseline were confirmed by additional information sources, which include the following depending on the available options in the different countries: contact with a medical practitioner, use of diabetes-related medication (eg, insulin and blood-glucose-lowering drugs), repeated self-report during follow-up, linkage to diabetes registries or a measure of glycated haemoglobin (HbA1c) above 6%. A total of 5542 cases of diabetes mellitus could be confirmed. We also included 870 participants whose diabetes diagnosis was confirmed within another project in EPIC, leading to a subcohort of 6412 individuals with confirmed diabetes at baseline. For the current study, only EPIC study centres that could provide data on SRH were included (Germany: Heidelberg and Potsdam; the Netherlands: Bilthoven; Sweden: Umeå). For this reason, 3155 participants (from the centres in Denmark, Italy and Spain) were excluded. The final data set therefore comprised 3257 participants from four EPIC study centres with a confirmed diagnosis of diabetes mellitus at baseline. No clear separation between type 1 and type 2 diabetes could be made.

**Assessment of SRH**

SRH was assessed at baseline using self-administered questionnaires in the native language. The questionnaires were somewhat differently formulated at each centre and were therefore standardised (described in online appendix). Given the low frequency of responses in the extreme categories (n=316 in the highest and n=241 in the lowest), we dichotomised the SRH variable by combining the two highest categories (high SRH) and the two lowest categories (low SRH) in conformity with previous studies.

**Covariates and outcome**

Weight and height were measured with participants not wearing shoes. Each participant’s body weight was corrected for clothing worn during measurement in order to reduce heterogeneity due to protocol differences among centres. Body mass index (BMI) was calculated after measurement of body weight and height, as weight (in kilograms) divided by height (in metres squared). Overweight was defined as a BMI of 25–29.9 kg/m² and obesity as ≥30 kg/m² according to the WHO guidelines. Underweight was defined as a BMI of <20 kg/m². Since there were only 43 persons with underweight, we merged underweight with the normal BMI category. For the blood pressure measurements, uniform procedures were recommended. Hypertension was defined by a hypertension diagnosis or use of hypertensive medication or blood pressure ≥140/90 mm Hg. Further health-related variables were collected using questionnaires, including questions on educational level, smoking status (current smoker vs non-smoker or ex-smoker), physical activity level and medical history including history of myocardial infarction (MI), stroke and cancer. Physical inactivity was defined using the Cambridge Index. Hyperlipidaemia was defined by use of medication for hyperlipidaemia.

Participants were followed from study entry until death, emigration, withdrawal or end of follow-up period. Causes and dates of deaths were ascertained using record linkages with central cancer registries, death indexes or by follow-up mailings and subsequent enquiries to municipality registries, regional health departments, physicians or hospitals. Mortality data were coded following the 10th revision of the International Classification of Diseases, Injuries and Causes of Death (ICD-10). ICD-10 codes I00–I99 were used to calculate proportions of cardiovascular mortality. HRs were calculated for all-cause mortality only since we

did not have statistical power for analyses of specified mortality.

**Statistical analyses**

\( \chi^2 \) Test was used for testing proportions in categorical variables. Kruskal–Wallis test was used for significance testing in continuous variables. HRs and 95% CIs were estimated using Cox proportional hazards models. Age was used as the primary time variable, with entry time defined as the subject’s age in years at recruitment and exit time defined as the subject’s age in years at death or censoring. Multivariate models were constructed to determine HRs adjusted for covariates. Age, centre, sex, BMI, physical inactivity, insulin treatment, hypertension and history of MI, stroke or cancer were tested as covariates and included in the multivariate model since they met the criteria of being significantly associated with both SRH and mortality during follow-up in men or in women. Given the low frequencies of previous MI, stroke and cancer, these covariates were combined in one variable in the multivariate analysis to ensure a good model fit. Interaction was tested by including interaction terms in the Cox proportional hazards analysis. The HRs were combined across centres using random-effects meta-analysis, and \( I^2 \)—the percentage of variation between centres due to real heterogeneity—was calculated. The first sensitivity analysis was performed to see if the strength of the association between SRH and mortality differed for short-term mortality and long-term mortality. Short-term mortality was defined as death within 5 years and long-term mortality as death after 5 years or more. This cut-off point was close to the median follow-up time of the decedents (5.4 years). The second sensitivity analysis was performed by excluding participants with underweight (BMI <20 kg/m²). A p value <0.05 was considered significant. All analyses were performed using SPSS Statistics V.19.0 except for the \( I^2 \) index test, which was performed using Comprehensive Meta-Analysis V.2.

**Missing values**

There was no information on history of stroke and cancer from the centre in Umeå (n=427), and these missing values were assigned to a separate category in multivariate analysis. The proportions of missing values for other variables were all <2.5% and coded as missing in multivariate analysis. Consequently, 85 persons including eight decedents were lost in the multivariate analysis.

**RESULTS**

The mean follow-up time was 8.6 years (±2.3). Baseline characteristics for the 1903 men and 1354 women are presented in table 1. Mean age at baseline was 56.2 years (±7.1) for men and 55.4 years (±8.2) for women. Among the 3257 persons included in the study, there were 241 deaths (13%) in men and 103 deaths (8%) in women. Of the 344 persons who died, 40% were cardiovascular deaths, 52% were non-cardiovascular deaths and in 8%, the cause of death was unknown.

<table>
<thead>
<tr>
<th>Table 1 Baseline characteristics of 3257 individuals with diabetes participating in the European Prospective Investigation into Cancer and Nutrition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong> (N=1903)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
</tr>
<tr>
<td><strong>Self-rated health</strong></td>
</tr>
<tr>
<td>Excellent</td>
</tr>
<tr>
<td>Good</td>
</tr>
<tr>
<td>Low</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Poor</td>
</tr>
<tr>
<td><strong>Education</strong></td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Primary school</td>
</tr>
<tr>
<td>Technical/professional school</td>
</tr>
<tr>
<td>Secondary school</td>
</tr>
<tr>
<td>Longer (including university degree)</td>
</tr>
<tr>
<td><strong>Body mass index (kg/m²)</strong></td>
</tr>
<tr>
<td><strong>Current smoking</strong></td>
</tr>
<tr>
<td><strong>Physical inactivity</strong></td>
</tr>
<tr>
<td><strong>Insulin treatment</strong></td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td><strong>Hyperlipidaemia</strong></td>
</tr>
<tr>
<td><strong>History of myocardial infarction</strong></td>
</tr>
<tr>
<td><strong>History of stroke</strong></td>
</tr>
<tr>
<td><strong>History of cancer</strong></td>
</tr>
</tbody>
</table>

Data are presented as per cent or mean (SD).

Table 2 shows the baseline characteristics in relation to categories of SRH. Persons with low SRH were younger, more frequently women, had higher BMI and had more frequently a history of MI or stroke compared to persons with high SRH. Moreover, in men with low SRH, insulin treatment was more common, and in women with low SRH, hypertension and a history of cancer were more common.

In a model adjusted for age and centre, low SRH was associated with increased mortality (table 3). In sex-specific analyses, this association was significant in men but not in women. After further adjustments for potential confounders, the association between low SRH and mortality was attenuated but remained significant in men and in both sexes combined. The fully adjusted HR for both sexes was 1.38 (95% CI 1.10 to 1.73). In a sensitivity analyses, we calculated HRs for low SRH for short-term mortality (participants who died within 5 years of follow-up, n=158) and long-term mortality (participants who died after 5 years or more, n=186). HR of low SRH for short-term mortality was 1.91 (95% CI 1.30 to 2.80) for men and 1.38 (95% CI 0.75 to 2.55) for women in the fully adjusted model. HR of low SRH for long-term mortality was 1.24 (95% CI 0.85 to 1.79) for men and 0.94 (95% CI 0.53 to 1.67) for women in the same multivariate model.

Interaction analyses were performed between SRH and covariates in relation to mortality. We found...
a significant interaction between SRH and BMI with $P_{\text{interaction}}$ value 0.03. When analysing HRs for SRH in different categories of BMI, we found stronger associations between SRH and mortality at lower levels of BMI, indicating an antagonistic interaction (table 4). For example, in the category normal or underweight, the fully adjusted HR for both sexes combined was 2.95 (1.71 to 5.10) compared to 1.14 (0.79 to 1.65) in obese individuals. Consequently, we performed a second sensitivity analysis by excluding persons with underweight (BMI < 20 kg/m², 43 persons) from the main analysis of SRH and mortality, which attenuated the fully adjusted HR from 1.38 to 1.36 (1.08 to 1.70) in both sexes combined.

We found no statistical interaction between SRH and sex ($P_{\text{interaction}}$ value 0.30), age ($P_{\text{interaction}}$ value 0.22), education level ($P_{\text{interaction}}$ value 0.14), smoking ($P_{\text{interaction}}$ value 0.13), physical inactivity ($P_{\text{interaction}}$ value 0.24), insulin treatment ($P_{\text{interaction}}$ value 0.18), hypertension ($P_{\text{interaction}}$ value 0.23), hyperlipidaemia ($P_{\text{interaction}}$ value 0.16) and history of MI, stroke or cancer ($P_{\text{interaction}}$ value 0.29).

**DISCUSSION**

We found that low SRH was associated with an increased risk of mortality in individuals with diabetes after adjusting for major established risk factors. This association was homogeneous across the four EPIC centres situated in three different European countries. The strength of the association between SRH and mortality in this study was similar to results in general populations. In sex-specific analyses, we found that the association between SRH and mortality was significant in men but not in women. However, the HR in women pointed in the same direction as in men, and we cannot rule out that the lack of significance was due to the lower statistical power to detect an association in women. Interestingly, the association between SRH and

---

**Table 2** Baseline characteristics in relation to categories of self-rated health

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Self-rated health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Excellent</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>Poor</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.1</td>
<td>56.6</td>
</tr>
<tr>
<td></td>
<td>55.2</td>
<td>55.4</td>
</tr>
<tr>
<td>Education (%)</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>0.07</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>0.08</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.6</td>
<td>28.4</td>
</tr>
<tr>
<td></td>
<td>28.9</td>
<td>29.0</td>
</tr>
<tr>
<td>Current smoking (%)</td>
<td>25.5</td>
<td>23.4</td>
</tr>
<tr>
<td></td>
<td>24.8</td>
<td>23.7</td>
</tr>
<tr>
<td>Physical inactivity (%)</td>
<td>20.6</td>
<td>26.3</td>
</tr>
<tr>
<td></td>
<td>26.6</td>
<td>41.1</td>
</tr>
<tr>
<td>Insulin treatment (%)</td>
<td>15.2</td>
<td>20.8</td>
</tr>
<tr>
<td></td>
<td>27.4</td>
<td>29.2</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>67.5</td>
<td>68.5</td>
</tr>
<tr>
<td></td>
<td>74.0</td>
<td>70.7</td>
</tr>
<tr>
<td>Hyperlipidaemia (%)</td>
<td>22.0</td>
<td>20.4</td>
</tr>
<tr>
<td></td>
<td>24.1</td>
<td>21.8</td>
</tr>
<tr>
<td>History of myocardial infarction (%)</td>
<td>9.0</td>
<td>6.9</td>
</tr>
<tr>
<td></td>
<td>11.5</td>
<td>17.3</td>
</tr>
<tr>
<td>History of stroke (%)</td>
<td>2.8</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>4.5</td>
<td>9.5</td>
</tr>
<tr>
<td>History of cancer (%)</td>
<td>5.1</td>
<td>5.1</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>5.7</td>
</tr>
</tbody>
</table>

Data are presented as per cent or mean.

---

**Table 3** HRs of low (moderate or poor) versus high (excellent or good) self-rated health for all-cause mortality during follow-up

<table>
<thead>
<tr>
<th></th>
<th>Model 1*, HR (95% CI)</th>
<th>Model 2†, HR (95% CI)</th>
<th>Model 3‡, HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>1.56 (1.25 to 1.94)</td>
<td>1.49 (1.19 to 1.86)</td>
<td>1.38 (1.10 to 1.73)</td>
</tr>
<tr>
<td>Men</td>
<td>1.75 (1.35 to 2.27)</td>
<td>1.63 (1.25 to 2.12)</td>
<td>1.52 (1.16 to 1.98)</td>
</tr>
<tr>
<td>Women</td>
<td>1.35 (0.90 to 2.03)</td>
<td>1.21 (0.80 to 1.83)</td>
<td>1.11 (0.73 to 1.69)</td>
</tr>
</tbody>
</table>

*Adjusted for age and centre.
†Adjusted for age, centre, sex, body mass index, physical inactivity, insulin treatment and hypertension.
‡Adjusted for age, centre, sex, body mass index, physical inactivity, insulin treatment, hypertension and history of myocardial infarction, stroke or cancer.

---

Figure 1 shows a forest plot with adjusted HRs for low SRH by sex and in both sexes combined for each centre. We found no clear indication of heterogeneity in the association between SRH and mortality across centres ($I^2$ index=0).
mortality was stronger among individuals with BMI of <25 kg/m² than among obese individuals in both men and women. This finding could possibly be explained by the presence of other chronic diseases leading to low body weight, low SRH and higher risk of premature death. However, the association between low SRH and mortality remained significant even after the exclusion of persons with BMI of <20 kg/m². Therefore, there are likely other factors contributing to the weaker association between SRH and overall mortality in obese individuals with diabetes. First, we found that the proportion of cardiovascular mortality was highest among obese individuals in both men and women, suggesting that the mortality pattern may be different at different levels of BMI. Previous research has shown that the link between SRH and mortality may be weaker for cardiovascular mortality than for cancer mortality or mortality from other causes.\textsuperscript{30} Second, we found that the obese individuals rated their health lower than individuals with normal weight, which is in line with studies on general populations.\textsuperscript{31} Previous studies have shown that obese persons may experience discrimination, stigmatisation and major limitations in daily life linked to their obesity.\textsuperscript{32,33} These factors will likely have a considerable impact on their health perception. We hypothesise that these factors related to obesity may overshadow other important health problems or health behaviours in the perception of health and possibly weaken the association between SRH and mortality in obese individuals.

Table 4 HRs of low versus high self-rated health for all-cause mortality by categories of BMI

<table>
<thead>
<tr>
<th>BMI classification</th>
<th>BMI (kg/m²)</th>
<th>CV mortality (%)</th>
<th>Model 1*, HR (95% CI)</th>
<th>Model 2†, HR (95% CI)</th>
<th>Model 3‡, HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes Normal or underweight (n=646)</td>
<td>&lt;25</td>
<td>38.3</td>
<td>2.81 (1.65 to 4.79)</td>
<td>3.12 (1.81 to 5.37)</td>
<td>2.95 (1.71 to 5.10)</td>
</tr>
<tr>
<td>Overweight (n=1408)</td>
<td>25–29.9</td>
<td>37.3</td>
<td>1.46 (1.05 to 2.03)</td>
<td>1.34 (0.96 to 1.89)</td>
<td>1.22 (0.87 to 1.71)</td>
</tr>
<tr>
<td>Obesity (n=1203)</td>
<td>≥30</td>
<td>45.0</td>
<td>1.29 (0.90 to 1.85)</td>
<td>1.20 (0.83 to 1.72)</td>
<td>1.14 (0.79 to 1.65)</td>
</tr>
<tr>
<td>Men Normal or underweight (n=359)</td>
<td>&lt;25</td>
<td>39.5</td>
<td>2.77 (1.49 to 5.15)</td>
<td>3.61 (1.90 to 6.85)</td>
<td>3.57 (1.88 to 6.78)</td>
</tr>
<tr>
<td>Overweight (n=921)</td>
<td>25–29.9</td>
<td>39.0</td>
<td>1.62 (1.12 to 2.36)</td>
<td>1.45 (0.99 to 2.14)</td>
<td>1.33 (0.90 to 1.95)</td>
</tr>
<tr>
<td>Obesity (n=623)</td>
<td>≥30</td>
<td>47.5</td>
<td>1.57 (1.00 to 2.47)</td>
<td>1.38 (0.87 to 2.18)</td>
<td>1.31 (0.83 to 2.08)</td>
</tr>
<tr>
<td>Women Normal or underweight (n=287)</td>
<td>&lt;25</td>
<td>35.3</td>
<td>3.14 (1.10 to 8.94)</td>
<td>2.47 (0.79 to 7.66)</td>
<td>1.87 (0.59 to 6.00)</td>
</tr>
<tr>
<td>Overweight (n=487)</td>
<td>25–29.9</td>
<td>31.4</td>
<td>1.20 (0.61 to 2.38)</td>
<td>1.04 (0.51 to 2.11)</td>
<td>0.93 (0.45 to 1.91)</td>
</tr>
<tr>
<td>Obesity (n=580)</td>
<td>≥30</td>
<td>41.2</td>
<td>1.05 (0.56 to 3.85)</td>
<td>0.95 (0.52 to 1.74)</td>
<td>0.92 (0.50 to 1.69)</td>
</tr>
</tbody>
</table>

*Adjusted for age and centre.†Adjusted for age, centre, sex, BMI, physical inactivity, insulin treatment and hypertension.‡Adjusted for age, centre, sex, BMI, physical inactivity, insulin treatment, hypertension and history of myocardial infarction, stroke or cancer.

BMI, body mass index; CV, cardiovascular.

Figure 1 Forest plot showing adjusted HRs and 95% CIs for the centres included in the study investigating the association between low self-rated health and mortality in individuals with diabetes.
Diabetes, self-rated health and mortality

The association between SRH and mortality has been of interest in medical research for several decades. Already in 1973, Maddox, one of the pioneers in this research field stated that SRH “clearly measure something more—and something less—than objective medical ratings”.

It is still debated what information individuals rely on when rating their health. Qualitative research has suggested that SRH reflects a combination of specific health problems, general physical functioning and health behaviours. Cultural differences may also have an impact on SRH, even within Europe.

A previous quantitative study from The National Health and Nutrition Examination Survey (NHANES) found that low SRH is particularly predictive for respondents with self-reported history of circulatory system diagnoses and perception of symptoms but not for respondents without symptoms or diagnoses.

Only a few studies have evaluated the association between SRH and mortality in well-defined cohorts of patients with diabetes.

In 1994, Dasbach and colleagues found increased mortality in 987 patients with older onset of diabetes who rated their health as worse than other people of similar age. The average age in their study was 64.7 years (±11.0) compared to 55.8 years (±7.6) in our study. More recently, McEwen and coworkers found that SRH predicted mortality in an American multiethnic cohort of over 7000 patients with diabetes. However, their study was restricted to patients with longer duration of diabetes (diagnosed at least 18 months before survey) in managed care and a relatively short follow-up (the average length was 3.7 years). In the FIELD study, a controlled trial of fenofibrate performed in Australia, New Zealand and Finland, the mean duration of follow-up was even shorter, only 2.4 years. In this study involving 7348 patients with diabetes, Clarke and colleagues found that low SRH was associated with vascular events, diabetes complications and all-cause mortality. In our study, which was population-based, the participants were younger and followed for an average of 8.6 years. We found that the association between SRH and mortality was weaker and no longer statistically significant when we restricted the analysis to long-term mortality. These findings raise questions about the long-term predictiveness of a single self-rating of health and we therefore suggest that future research in individuals with diabetes should include repeated self-ratings and follow-up for long-term mortality.

There are some limitations in our study. Even if the association between SRH and mortality was robust when individuals with underweight were excluded, we cannot rule out other potential residual confounding from comorbidity other than MI, stroke or cancer that was not assessed at baseline health examinations. Moreover, the sample size in the present study did not allow any clear conclusions in relation to sex-specific analyses, and we could not make a separation between type 1 and type 2 diabetes. The questions and the response alternatives on SRH were formulated somewhat differently and in the native language at each centre. The questions and answers were translated and standardised in four response alternatives, which may have led to some degree of misclassification, particularly for the centres in Bilthoven and Umeå (which had five response alternatives). However, the forest plot gave no indication that the standardisation in four response alternatives had a major impact on the risk estimates. The multivariate models used in this study were similar but not identical with equations used in risk engines and risk scores.

Whether SRH adds predictive value over and above these models needs to be further analysed in future studies using adequate methods.

Although more research is needed to gain a more complete understanding of the relationship between SRH and mortality in individuals with diabetes, we find that self-ratings of health are an inexpensive and time-efficient way to obtain subjective prognostic information that may be difficult to assess by objective health measurements. In patients with diabetes with low SRH, the physician should consider a more detailed consultation and intensified support.

Conclusions

This is the first study investigating the association between SRH and mortality in individuals with diabetes with a long-term follow-up in different European countries. We found that low SRH was associated with increased mortality in individuals with diabetes after controlling for established risk factors. The association was mainly driven by increased 5-year mortality in men and was stronger among individuals with BMI of <25 kg/m² than among obese individuals.

Contributors

PW, OR and UN were involved in the study concept and planned the analyses. PW, OR, HB, DS, RK, BT, AS, BBoM and UN contributed in the acquisition of the data. PW was responsible for statistical analyses and drafted the paper. PW, OR, LJ and UN interpreted the results. All authors participated in critical revision of the manuscript and approved the final version. PW is the guarantor.

Funding

This study was supported by a European Foundation for the Study of Diabetes/Sanofi-Aventis grant. The European Foundation for the Study of Diabetes or Sanofi-Aventis had no role in the design or conduct of the study, collection or analysis of the data or preparation or approval of the manuscript and did not have any influence on the contents.
Competing interests All authors have completed the Unified Competing Interest form at http://www.icmje.org/doiDisclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval Ethics approval was provided by the IARC Institutional Review Board.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

REFERENCES
Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study

Patrik Wennberg, Olov Rolandsson, Lars Jerdén, et al.

BMJ Open 2012 2:
doi: 10.1136/bmjopen-2011-000760

Updated information and services can be found at:
http://bmjopen.bmj.com/content/2/1/e000760.full.html

These include:

Data Supplement
"Supplementary Data"
http://bmjopen.bmj.com/content/suppl/2012/02/14/bmjopen-2011-000760.DC1.html

References
This article cites 37 articles, 10 of which can be accessed free at:
http://bmjopen.bmj.com/content/2/1/e000760.full.html#ref-list-1

Article cited in:
http://bmjopen.bmj.com/content/2/1/e000760.full.html#related-urls

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See:
http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Articles on similar topics can be found in the following collections

- Diabetes and endocrinology (73 articles)
- General practice / family practice (128 articles)
- Patient-centred medicine (82 articles)
- Epidemiologic studies (73 articles)
- Stroke (10 articles)
- Hypertension (13 articles)
- Diabetes (12 articles)
- Metabolic disorders (13 articles)
- Lipid disorders (1 articles)
- Drugs: cardiovascular system (19 articles)
- Health education (27 articles)
- Health promotion (30 articles)
- Ischaemic heart disease (13 articles)
- Smoking (16 articles)
- Smoking and tobacco (16 articles)
- Obesity (nutrition) (11 articles)
- Obesity (public health) (11 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/